Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

NCT05391724 | Completed Phase 1

• 1 other identifier: CMX001-106
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 3

Brief Summary

This is an open-label, non-randomized, multi-center, sequential group, safety, tolerance, and Pharmacokinetic study of a single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg in fasted healthy control subjects compared with that in fasted subjects with moderate and severe hepatic impairment.

Conditions

Hepatic Impairment

Keywords

hepatic impairment

Outcome Measures

Primary Outcomes (1)

• Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0

  An objective of this study was to determine the safety following administration of a single dose of CMX001 in subjects with moderate and severe hepatic impairment compared to match subjects with normal hepatic function.

  6 months

Secondary Outcomes (3)

• Maximum concentration (Cmax) of moderate and severe hepatic impairment after a single dose of CMX001

  6 months

• Time to maximum concentration (Tmax) of moderate and severe hepatic impairment after a single dose of CMX001

  6 months

• Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) of moderate and severe hepatic impairment after a single dose of CMX001

  6 months

Study Arms (1)

CMX001

EXPERIMENTAL

single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg

Drug: CMX001

Interventions

CMX001 DRUG

single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg

Also known as: Brincidofovir, BCV

CMX001

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to comprehend and willing to sign an informed consent form (ICF);
• Male or female subjects, between 18 and 65 years of age, inclusive;
• Within body mass index (BMI) range 18 to 40 kg/m2, inclusive;
• Negative test for selected drugs of abuse at Screening (does not include alcohol) and at Check-in (does include alcohol); positive drug screens in the hepatically-impaired subjects may be allowed with the confirmation of use of the medication under supervision of a physician)
• Negative HIV antibody and hepatitis B surface antigen (HBsAg) screens;
• Female subjects will be non-pregnant, non-lactating, and either postmenopausal for at least 1 year (with follicle-stimulating hormone (FSH) levels ≥40 mIU/mL), surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days, or agree to use from the time of signing the ICF until 30 days after Study Discharge one of the following forms of contraception: a non-hormonal intrauterine device (IUD) with spermicide; female condom with spermicide; contraceptive sponge with spermicide; a non-hormonal intravaginal system; diaphragm with spermicide; cervical cap with spermicide; a male sexual partner who agrees to use a male condom with spermicide; or a sterile sexual partner; for all female subjects, the pregnancy test result must be negative at Screening and Check-in;
• Male subjects will either be sterile or agree to use from Check-in until 45 days following Study Discharge one of the following approved methods of contraception: a male condom with spermicide; a sterile sexual partner; or use by female sexual partner of an IUD with spermicide; a female condom with spermicide; contraceptive sponge with spermicide; an intravaginal system (e.g., NuvaRing®); a diaphragm with spermicide; a cervical cap with spermicide; or oral, implantable, transdermal, or injectable contraceptives.
• For healthy subjects with normal hepatic function:
• Normal hepatic function defined as alanine aminotransferase, aspartate aminotransferase, bilirubin, serum albumin, and gamma glutamyl transferase all within normal limits;
• The absence of clinically-relevant abnormalities identified by a detailed medical history, full physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests;
• Negative hepatitis panel (including HBsAg and hepatitis C virus antibody);
• No medical or surgical conditions that might significantly interfere with gastrointestinal absorption of CMX001.
• For subjects with impaired hepatic function:
• Otherwise healthy subjects as determined by a detailed medical history, complete physical examination, vital signs, 12-lead ECG, and clinical laboratory tests (abnormal findings that are related to the subject's underlying condition are acceptable);
• Satisfy the criteria for Class B or Class C of the modified Child-Turcotte-Pugh (CPT) classification (mild \[CPT score of 5 to 6 points\], moderate \[CPT score of 7 to 9 points\], and severe \[CPT score of \>9 to \<12 points\]);

You may not qualify if:

• Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic (healthy control subjects only), renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator, Sponsor, and/or Sponsor's representative);
• Any non-hepatic disease or condition that could affect safety or data interpretation (as determined by the Investigator, Sponsor, and/or Sponsor's representative);
• History of significant hypersensitivity, intolerance, or allergy to any drug compound, including cidofovir (CDV), food, or other substance, unless approved by the Investigator, Sponsor, and/or Sponsor's representative;
• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy and/or hernia repair will be allowed;
• History of any condition possibly affecting drug absorption (e.g., gastrectomy, active peptic ulcer) within the last 3 months;
• serum albumin \<3 g/dL;
• History or presence of an abnormal ECG, which, in the opinion of the Investigator, Sponsor, and/or Sponsor's representative, is clinically significant;
• History of alcoholism or drug addiction within 1 year prior to Check-in (healthy control subjects only);
• Use of any tobacco- or nicotine-containing products within 6 months prior to Check-in (healthy control subjects only);
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days (or 5 half-lives, whichever is longer) prior to Check-in;
• Use of oral, implantable, injectable, or transdermal contraceptives within 14 days prior to Check-in (female subjects only);
• For healthy control subjects, use of any prescription medications/products within 14 days prior to Check-in, unless deemed acceptable by the Investigator and Sponsor;
• For healthy control subjects, use of any over-the-counter (OTC), non-prescription preparations (including vitamins, minerals, and phytotherapeutic/ herbal/plant-derived preparations) within 7 days prior to Check-in, unless deemed acceptable by the Investigator, Sponsor, and/or Sponsor's representative;
• Use of alcohol-, grapefruit-, or caffeine-containing foods or beverages within 72 hours prior to Check-in, unless deemed acceptable by the Investigator, Sponsor, and/or Sponsor's representative;
• Poor peripheral venous access;

Sponsors & Collaborators

• Jazz Pharmaceuticals: lead

Study Sites (3)

Elite Research

Miami, Florida, 33169, United States

Location

Orlando Clinical Research Center

Orlando, Florida, 32809, United States

Location

DaVita Clinical Research

Minneapolis, Minnesota, 55404, United States

Location

MeSH Terms

Interventions

brincidofovir

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 30, 2011
• First Posted: May 26, 2022
• Study Start: February 1, 2011
• Primary Completion: September 1, 2011
• Study Completion: September 1, 2011
• Last Updated: May 26, 2022

Record last verified: 2022-05

Locations

US (3)